BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: BMS is a global pharmaceutical and health care company organized into three reportable segments: Pharmaceuticals, Nutritionals (Mead Johnson), and Other Health Care (ConvaTec, Medical Imaging, and Consumer Medicines). The company is currently executing a strategic transition to shift its portfolio from products losing market exclusivity to growth drivers and new products addressing unmet medical needs.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 1% to $19.2 billion in 2005, driven by a 2% decline in the Pharmaceuticals segment due to exclusivity losses (e.g., PARAPLATIN, GLUCOPHAGE franchise) and increased competition for PRAVACHOL. This was partially offset by growth in Nutritionals (up 10%) and new product launches.
• Profitability Increase: Earnings from continuing operations increased 26% to $2.99 billion. This improvement was primarily due to a lower effective tax rate (20.6% vs. 34.4% in 2004) resulting from the release of tax reserves and a reduction in the deferred tax charge related to the repatriation of foreign earnings under the American Jobs Creation Act (AJCA).
• Divestitures: The company recorded a pre-tax gain of $569 million from the sale of its U.S. and Canadian Consumer Medicines business to Novartis in Q3 2005. Additionally, a pre-tax gain of $63 million was recorded from the sale of Oncology Therapeutics Network (OTN), which is now reported as discontinued operations.
• Cost Structure: Research and development expenses increased 10% to $2.75 billion, reflecting continued investment in late-stage compounds. Litigation charges decreased 36% to $269 million, aided by $321 million in insurance recoveries.

Guidance, Outlook, and Risks

• 2006 Outlook: Management anticipates net sales reductions of $1.4 billion to $1.5 billion in 2006 due to continued exclusivity losses (specifically PRAVACHOL in the U.S. and Europe, and CEFZIL). These declines are expected to be offset by growth in key drivers like PLAVIX, ABILIFY, and REYATAZ. Gross margins are expected to stabilize.
• 2007 Outlook: The company expects to enter a period of sustained growth in 2007 as exclusivity losses moderate and productivity savings initiatives (targeting $500 million in savings) begin to materialize.
• Key Risks:
  • PLAVIX Litigation: The company's largest product ($3.8 billion in 2005 sales) faces patent litigation in the U.S. and Canada. A trial is scheduled for June 2006. An adverse outcome could lead to generic competition, materially impacting sales and cash flows.
  • Legal Contingencies: The company faces numerous lawsuits regarding pricing, sales practices, and product liability. Management believes the aggregate impact beyond current reserves is reasonably likely to be material to results of operations.
  • Regulatory & Pricing: Ongoing pressure from government cost-containment programs and managed care organizations continues to impact pricing and reimbursement.

Investor Verification Checklist

• PLAVIX Patent Status: Verify the outcome of the U.S. patent infringement trial scheduled for June 2006 and the potential for generic entry by Apotex.
• Exclusivity Loss Timeline: Confirm the actual sales impact of PRAVACHOL exclusivity loss in the U.S. (April 2006) and Europe.
• Legal Reserves: Monitor updates on litigation reserves, particularly regarding the Average Wholesale Price (AWP) litigation and pricing investigations, as actual losses may exceed current accruals.
• Product Pipeline: Track regulatory approvals for key pipeline compounds, including dasatinib (CML), ORENCIA (rheumatoid arthritis), and EMSAM (depression).
• Deferred Tax Assets: Assess the realizability of foreign tax credit and research tax credit carryforwards ($975 million and $120 million, respectively), which depend on future domestic profitability and the outcome of PLAVIX litigation.